Siunpharma looks week in daily chart and seems it can fall 1680 zone as per price support on that area where bulls vcan activate and bears will close their position.
📈 Technical Indicators
Moving Averages: Strong Sell
Technical Indicators: Strong Sell
RSI (14): 31.939 (Approaching oversold territory)
MACD (12,26): -13.57 (Bearish)
ADX (14): 30.04 (Indicates trend strength)
Williams %R: -97.69 (Oversold)
🔍 Demand & Resistance Zones
Demand Zone: ₹1,840–₹1,850
Sellers' Liquidity Zone: ₹1,920
Major Resistance: ₹1,960 (All-time high on Sep 30, 2024)
📌 Trade Setup
Entry: Consider long positions near ₹1,850 or upon breakout above ₹1,860
Targets:
Target 1: ₹1,920
Target 2: ₹1,960
Stop-Loss: Below ₹1,820
Risk-Reward Ratio: Minimum 1:2
🧠 Fundamental Insights
Analyst Consensus: Buy
12-Month Price Target: Average ₹2,051.84 (Upside of ~14.98%)
EPS Growth Forecast: 12.3% per annum
Revenue Growth Forecast: 9.8% per annum
Return on Equity Forecast: 16.9% over 3 years
🧬 Recent Developments
Acquisition: Acquired Checkpoint Therapeutics for $355 million in March 2025, enhancing oncology portfolio
Earnings Beat: Q3 FY25 EPS of ₹13.40 vs. estimate of ₹11.98; Revenue of ₹136.75B vs. estimate of ₹133.98B
📈 Technical Indicators
Moving Averages: Strong Sell
Technical Indicators: Strong Sell
RSI (14): 31.939 (Approaching oversold territory)
MACD (12,26): -13.57 (Bearish)
ADX (14): 30.04 (Indicates trend strength)
Williams %R: -97.69 (Oversold)
🔍 Demand & Resistance Zones
Demand Zone: ₹1,840–₹1,850
Sellers' Liquidity Zone: ₹1,920
Major Resistance: ₹1,960 (All-time high on Sep 30, 2024)
📌 Trade Setup
Entry: Consider long positions near ₹1,850 or upon breakout above ₹1,860
Targets:
Target 1: ₹1,920
Target 2: ₹1,960
Stop-Loss: Below ₹1,820
Risk-Reward Ratio: Minimum 1:2
🧠 Fundamental Insights
Analyst Consensus: Buy
12-Month Price Target: Average ₹2,051.84 (Upside of ~14.98%)
EPS Growth Forecast: 12.3% per annum
Revenue Growth Forecast: 9.8% per annum
Return on Equity Forecast: 16.9% over 3 years
🧬 Recent Developments
Acquisition: Acquired Checkpoint Therapeutics for $355 million in March 2025, enhancing oncology portfolio
Earnings Beat: Q3 FY25 EPS of ₹13.40 vs. estimate of ₹11.98; Revenue of ₹136.75B vs. estimate of ₹133.98B
거래청산: 타겟 닿음
Sunpharma low was 1626 target achieved and its 100 point fall. amazing trade.Join my Educational Telegram channel:
t.me/bullsbearsclub
My YouTube channel: youtube.com/channel/UC537A
My Indicator details:
docs.google.com/document/d/17wUSbSJEZR6rTNVdwqLEBaKM-CSYx-61TN0qazvsnAQ/edit?usp=sharing
t.me/bullsbearsclub
My YouTube channel: youtube.com/channel/UC537A
My Indicator details:
docs.google.com/document/d/17wUSbSJEZR6rTNVdwqLEBaKM-CSYx-61TN0qazvsnAQ/edit?usp=sharing
면책사항
이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.
Join my Educational Telegram channel:
t.me/bullsbearsclub
My YouTube channel: youtube.com/channel/UC537A
My Indicator details:
docs.google.com/document/d/17wUSbSJEZR6rTNVdwqLEBaKM-CSYx-61TN0qazvsnAQ/edit?usp=sharing
t.me/bullsbearsclub
My YouTube channel: youtube.com/channel/UC537A
My Indicator details:
docs.google.com/document/d/17wUSbSJEZR6rTNVdwqLEBaKM-CSYx-61TN0qazvsnAQ/edit?usp=sharing
면책사항
이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.